This website contains information intended only for persons professionally dealing with medical devices (e.g. for persons performing medical professions, for persons dealing with the distribution of medical devices). Please confirm that you are a medical device professional to proceed.
September 26, 2022
On 22.09.2022, during the XXVI International Congress of the Polish Cardiac Society in Katowice, a specially appointed PTK Competition Committee recognized the Cardiolens FFR-CT Pro® diagnostic platform as the most innovative product presented at the conference.
This prestigious competition held in the Digital Cardio Arena zone was to select and reward the most innovative ideas, technological discoveries and solutions related to the prevention and treatment of cardiovascular diseases.
Digital Cardio Arena is a zone dedicated primarily to projects in the start-up phase and innovations that are being worked on in medical institutes and universities, as well as solutions already implemented on the market.
From among all submitted projects, three companies were marked out, which wee nominated to the next stage and were invited to present their ideas during the congress.
By the decision of the Competition Committee, the winner was the platform for non-invasive diagnostics of coronary artery disease – Cardiolens FR-CT Pro® developed by the European-based company Hemolens Diagnostics. The system will enable cardiologists to perform an accurate and precise anatomical and functional assessment of the coronary arteries, enabling non-invasive diagnostics in an outpatient setting, reducing the number of invasive procedures and the risk to the patient.
During the ceremonial inauguration of the Congress, the award for Hemolens Diagnostics was received by:
– Kryspin Mirota PhD Eng. – Founder and CSO
– Wojciech Tarnawski PhD Eng. – Founder and CTO
– Michał Stachowiak – Clinical Education Specialist.
Wojciech Jeżewski – Hemolens Diagnostics CEO: We are very pleased with this award. This is another proof that what we do makes great sense and we can have a real impact on reducing invasive procedures in the diagnostics of ischemic heart disease.
Hemolens Diagnostics is a technology company operating in the area of LifeScience and Healthcare. The main profile of the company’s activity is the use of innovative proprietary digital tools to develop and implement the Cardiolens FFR-CT Pro® digital platform for non-invasive diagnostics and monitoring of coronary artery disease. This cutting adge solution has the potential to revolutionize the health system in the diagnostics of ischemic heart disease. The company’s mission is to reduce the number of existing diagnostic methods based on invasive techniques and requiring hospitalization, enabling access to more accurate, safe and patient-friendly methods of diagnostics and treatment.
March 1, 2023
Rebranding is a process aimed at changing one or more elements of a brand’s image communication. This includes changes...
February 24, 2023
The research project ‘HEMOFLOW cloud platform for non-invasive hemodynamic diagnostics’, No. POIR.01.01.01-00-0393/19, aims to assess the diagnostic value of...
January 11, 2023
What is FFR Measuring fractional flow reserve (FFR) is currently the ‘gold standard’ in the diagnostic assessment of coronary...
November 21, 2022
On 10 November at the ISPOR 2022 Europe conference, independent research company Panaxea presented the results of a study...
October 11, 2022
On October 7-8th, 2022 the 14th edition of the “New developments in interventional cardiology” congress took place in Augustow (Poland),...
September 2, 2022
Cardiolens FFR-CT Pro® is a precise diagnostic test, supporting doctors in diagnosing patients with suspected ischemic heart disease. Cardiolens...
August 30, 2022
Atherosclerosis and the coronary artery disease that progresses with it is the most common cause of heart failure. In...
August 19, 2022
The Hemolens research project aims to assess the diagnostic value of the Hemolens platform for comprehensive, non-invasive diagnostics of...